January 18, 2017 4:36pm

 

PSTI  increased their offering or 12.244 M shares (versus 8.1 M at $1.225 share) together with warrants to purchase of at least 7.346 M shares of common stock with an exercise price of $1.40 per share of common stock  …

SELL

Pricing in the pre-market is DOWN -$0.37 ... to $1.03 or -26.43%

 


 

Since early December, PSTI had announced six developments that have moved its development platform forward with the nearest milestone set for the first half of this year.

 

Yet the shares have NOT appreciated.

  • The programs involved are its P3 trial for PLX-PAD placental stem cell treatment for critical limb ischemia (CLI), P2 for PLX-PAD for intermittent claudication (IC) and its animal rule study of PLX-R18 for acute radiation syndrome (ARS) …

 

The Bottom Line: A little tight in … initiating trial as related to an “extension” investments by Chinese companies? China-based Innovative Medical Management Co., Ltd. (stock code: 002173), extend the time of execution of the definitive agreements for Innovative Medical’s proposed investment of $30 M.  As a result of the recently adopted Chinese policy, the parties now plan to continue the discussions with respect to the definitive agreements until they have received further clarification about such policies, which is expected during the first half of 2017.

SELL